methyl N-Boc-2-oxazolidinone-4-carboxylate | 113525-83-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-Boc-2-oxazolidinone-4-carboxylate
• 英文别名: N-boc-4-methoxycarbonyloxazolidin-2-one；3-O-tert-butyl 4-O-methyl 2-oxo-1,3-oxazolidine-3,4-dicarboxylate
• CAS: 113525-83-0
• 化学式: C₁₀H₁₅NO₆
• 分子量: 245.232
• InChiKey: UIBHKFHEXZKPTC-UHFFFAOYSA-N

物化性质

• 沸点：
  291.2±50.0 °C(Predicted)
• 密度：
  1.276±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl N-Boc-2-oxazolidinone-4-carboxylate 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 tert-butyl (2-oxo-1,3-oxazolidin-4-yl)methyl carbonate
  参考文献：
  名称：

  [EN] OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA
  [FR] DERIVES DE L'OXAZOLIDIN-2-ONE ET DE LA THIAZOLIDIN-2-ONE ANTAGONISTES DU RECEPTEUR EP4, POUR LE TRAITEMENT DU GLAUCOME

  摘要：

  这项发明涉及公式（I）的化合物，它们是前列腺素E2受体EP4亚型的有效选择性激动剂，它们的使用或配方可用于治疗青光眼和其他与患者眼内压升高相关的疾病。

  公开号：

  WO2004019938A1
• 作为产物：
  描述：

  碳酸二叔丁酯 、 甲基2-氧代-1,3-恶唑烷-4-羧酸酯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 methyl N-Boc-2-oxazolidinone-4-carboxylate
  参考文献：
  名称：

  [EN] OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA
  [FR] DERIVES DE L'OXAZOLIDIN-2-ONE ET DE LA THIAZOLIDIN-2-ONE ANTAGONISTES DU RECEPTEUR EP4, POUR LE TRAITEMENT DU GLAUCOME

  摘要：

  这项发明涉及公式（I）的化合物，它们是前列腺素E2受体EP4亚型的有效选择性激动剂，它们的使用或配方可用于治疗青光眼和其他与患者眼内压升高相关的疾病。

  公开号：

  WO2004019938A1

文献信息

• Mild and selective ring-cleavage of cyclic carbamates to amino alcohols
  作者：Tadao Ishizuka、Takehisa Kunieda

  DOI：10.1016/s0040-4039(00)95574-6

  日期：——

  N-tert-Butoxycarbonylated 2-oxazolidinones and tetrahydro-2-oxazinones are smoothly cleaved to acyclic N-Boc-amino alcohols on treatment with catalytic amounts of cesium carbonate at room temperature. The versatility of the procedure is demonstrated in a facile cleavage of highly functionalized heterocycles without epimerization and β-elimination.

  在室温下用催化量的碳酸铯处理后，将N-叔丁氧基羰基化的2-恶唑烷酮和四氢-2-恶嗪酮平稳裂解为无环N-Boc-氨基醇。该方法的多功能性可在不进行差向异构和β-消除的情况下轻松裂解高度官能化的杂环中得到证明。
• Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
  申请人：Han Yongxin

  公开号：US20060154899A1

  公开（公告）日：2006-07-13

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  本发明涉及E2前列腺素受体EP4亚型的高效选择性激动剂，以及它们在治疗青光眼和其他与患者眼内压升高有关的疾病中的使用或配制。本发明还涉及本发明化合物在介导成骨细胞和破骨细胞的骨建模和重塑过程中的使用。
• EP4 receptor agonist, compositions and methods thereof
  申请人：Han Yongxin

  公开号：US20060270721A1

  公开（公告）日：2006-11-30

  This invention relates to potent selective agonists of the EP 4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  本发明涉及到前列腺素E2受体EP4亚型的有效选择性激动剂，其在治疗青光眼和其他与患者眼内高眼压相关的疾病的使用或制剂中的使用。本发明还涉及到利用本发明化合物介导成骨细胞和破骨细胞的骨建模和重塑过程的使用。
• Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma
  申请人：Merck & Co. Inc.

  公开号：US07109223B2

  公开（公告）日：2006-09-19

  This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

  本发明涉及到前列腺素E2受体EP4亚型的有效选择性激动剂，其在治疗青光眼和其他与患者眼内压升高有关的疾病的使用或制剂中的使用。本发明还涉及到利用本发明的化合物介导成骨细胞和破骨细胞的骨建模和重塑过程的使用。
• Di-<i>tert</i>-butyl Dicarbonate and 4-(Dimethylamino)pyridine Revisited. Their Reactions with Amines and Alcohols¹
  作者：Yochai Basel、Alfred Hassner

  DOI：10.1021/jo000257f

  日期：2000.10.1

  The reaction of BOC2O in the presence and absence of DMAP was examined with some amines, alcohols, diols, amino alcohols, and aminothiols. Often, unusual products were observed depending on the ratio of reagents, reaction time, polarity of solvent, pK(a) of alcohols, or type of amine (primary or secondary). In reactions of aliphatic alcohols with BOC2O/DMAP, we isolated for the first time carbonic-carbonic anhydride intermediates; this helps explain the formation of symmetrical carbonates in addition to the O-BOC products. In the case of secondary amines, we succeeded to isolate unstable carbamic-carbonic anhydride intermediates that in the presence of DMAP led to the final N-BOC product. The effect of N-methylimidazole in place of DMAP was also examined.